Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Regeneron, FDA and COPD
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical trials.
Sanofi's Dupixent scores double COPD win in US, China
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD -- as has China's National Medical Products Administration (NMPA) which announced its approval the same day. It's the first ever biologic medicine for COPD in either country.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
15h
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
19h
Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
'Harry Potter' star dies
Helene: How to help
High-end brothel plea
Troops to leave some bases
Promotes watch collection
ICE: Convicts roaming free
World's oldest cheese found
NC dam failure ‘imminent’
Killer gets life sentence
Urgent safety alert for 737s
50/50 ball ownership suit
Ending password-sharing
Fake Biden robocalls fine
Meta hit with privacy fine
Producing doc on Diddy
Boxes to distribute Narcan
Diocese reaches settlement
Van Gogh paintings attacked
Pleads not guilty
Fed inflation gauge cools
ISR targets Hezbollah HQ
US charges three Iranians
Bill to use birth control
KY sues Express Scripts
NY ballot appeal rejected
Deposition in AI suit
Dow closes at record high
Congressional Gold Medal
Feedback